Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy in Treatment-naïve Advanced NSCLC Patients Harbouring EGFR Exon 21 L858R Mutation: A Prospective, Multicenter, Randomized, Open Label Study (FLAIR)

NCT04988607 is registered in ClinicalTrials.gov with Guangdong Association of Clinical Trials as lead sponsor.

NCT NCT04988607
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04988607 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy in Treatment-naïve Advanced NSCLC Patients Harbouring EGFR Exon 21 L858R Mutation: A Prospective, Multicenter, Randomized, Open Label Study (FLAIR)
Lead sponsor
Guangdong Association of Clinical Trials
Phase
Phase 2
Overall status
Unknown status
Start date
August 31, 2021
Completion date
May 31, 2025
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer